Supraphysiological levels of GDF 11 induce striated muscle atrophy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Abstract Growth and differentiation factor (GDF) 11 is a member of the transforming growth factor β superfamily recently identified as a potential therapeutic for age‐related cardiac and skeletal muscle decrements, despite high homology to myostatin (Mstn), a potent negative regulator of muscle mass. Though several reports have refuted these data, the in vivo effects of GDF11 on skeletal muscle mass have not been addressed. Using in vitro myoblast culture assays, we first demonstrate that GDF11 and Mstn have similar activities/potencies on activating p‐SMAD2/3 and induce comparable levels of differentiated myotube atrophy. We further demonstrate that adeno‐associated virus‐mediated systemic overexpression of GDF11 in C57BL/6 mice results in substantial atrophy of skeletal and cardiac muscle, inducing a cachexic phenotype not seen in mice expressing similar levels of Mstn. Greater cardiac expression of Tgfbr1 may explain this GDF11‐specific cardiac phenotype. These data indicate that bioactive GDF11 at supraphysiological levels cause wasting of both skeletal and cardiac muscle. Rather than a therapeutic agent, GDF11 should be viewed as a potential deleterious biomarker in muscle wasting diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Identification of ubiquitin ligases required for skeletal muscle atrophy.
Bodine, S. C., Latres, E., Baumhueter, S., Lai, V. K.-M., Nunez, L., Clarke, B. A., Poueymirou, W. T., Panaro, F. J., Na, E., Dharmarajan, K., et al. (2001) · Science · doi:10.1126/science.1065874 · Cited by 3,521 · cited 3×
“Serum levels of ~60 lg/ml were estimated from the monomeric band [equating to ~3.3 mg/kg for a 23 g mouse (using the standard mouse blood volume of 0.055 ml/g bwt); Fig 3C], while in the quadriceps, monomeric GDF11 content was in the order of 0.001% of the total muscle protein (Fig 3D).”
BackgroundMethodResultInfluentialVascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors
Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S., Wojtkiewicz, G. R., Chen, J. W., Lee, R. T., Wagers, A. J., & Rubin, L. L. (2014) · Science · doi:10.1126/science.1251141 · Cited by 1,037 · cited 2×
“Rather than a therapeutic agent, GDF11 should be viewed as a potential deleterious biomarker in muscle wasting diseases.”
BackgroundLoffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., Sinha, M., Dall’Osso, C., Khong, D., Shadrach, J. L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.015 · Cited by 948 · cited 6×
“GDF11, which shares 90% homology with Mstn in its mature signaling peptide, has been the subject of recent reports proposing anti-aging effects in heart (Loffredo et al, 2013), skeletal muscle (Sinha et al, 2014), and brain (Katsimpardi et al, 2014).”
BackgroundMethodInfluentialRestoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle
Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., Miller, C., Regalado, S. G., Loffredo, F. S., Pancoast, J. R., et al. (2014) · Science · doi:10.1126/science.1251152 · Cited by 824 · cited 5×
“Rather than a therapeutic agent, GDF11 should be viewed as a potential deleterious biomarker in muscle wasting diseases.”
BackgroundInfluentialMyostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size
Trendelenburg, A. U., Meyer, A., Rohner, D., Boyle, J., Hatakeyama, S., & Glass, D. J. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00105.2009 · Cited by 792
Sacheck, J. M., Hyatt, J. K., Raffaello, A., Thomas Jagoe, R., Roy, R. R., Reggie Edgerton, V., Lecker, S. H., & Goldberg, A. L. (2007) · The FASEB Journal · doi:10.1096/fj.06-6604com · Cited by 585 · cited 2×
“These data suggest the striated muscle “atrogene” program is activated by systemic GDF11 overexpression; however, this activation is very modest in comparison with those shown by other atrophy models (Bodine et al, 2001; Sacheck et al, 2007).”
MethodResultGDF11 increases with age and inhibits skeletal muscle regeneration
Egerman, M. A., Cadena, S. M., Gilbert, J. A., Meyer, A., Nelson, H. N., Swalley, S. E., Mallozzi, C., Jacobi, C., Jennings, L. L., Clay, I., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.010 · Cited by 527 · cited 9×
“These data demonstrate that GDF11 causes atrophy in both skeletal and cardiac muscle, but only skeletal muscle atrophy is seen by overexpression of Mstn. Consistent with previous reports (Egerman et al, 2015) and the in vitro reporter assays described above, systemic elevation by AAV8.”
BackgroundMethodResultInfluentialMcPherron, A. C., Lawler, A. M., & Lee, S.-J. (1999) · Nature Genetics · doi:10.1038/10320 · Cited by 471 · cited 2×
“Keywords activin receptor; cachexia; cardiac atrophy; muscle mass; myostatin Subject Categories Ageing; Musculoskeletal System DOI 10.15252/emmm.201607231 | Received 23 October 2016 | Revised 26 January 2017 | Accepted 3 February 2017 | Published online 7 March 2017 EMBO Mol Med (2017) 9: 531–544”
BackgroundInfluentialBMP signaling controls muscle mass
Sartori, R., Schirwis, E., Blaauw, B., Bortolanza, S., Zhao, J., Enzo, E., Stantzou, A., Mouisel, E., Toniolo, L., Ferry, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2772 · Cited by 467
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 1×
“For ActRIIB antibody (antiActRIIB) assays, HEK293T cells were treated with 0 or 100 nM antiActRIIB (Creative BioMart, murinized version of BYM338 antibody; Lach-Trifilieff et al, 2014) overnight prior to ligand addition, lysing, and AlphaLISA evaluation, as described above.”
MethodGenetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238 · cited 1×
“While systemic manipulation (whether Mstn or dnMstn) and genetic deletion of Mstn display minimal effects in the heart despite dramatic changes to skeletal muscle, cardiac-specific expression of Mstn or dnMstn does affect cardiomyocyte size (Bish et al, 2010; Heineke et al, 2010).”
BackgroundThe bone morphogenetic protein axis is a positive regulator of skeletal muscle mass
Winbanks, C. E., Chen, J. L., Qian, H., Liu, Y., Bernardo, B. C., Beyer, C., Watt, K. I., Thomson, R. E., Connor, T., Turner, B. J., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201211134 · Cited by 225 · cited 1×
“Note that “a” on Day 2 of panel (C) refers to the 2 overlapping groups. ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 4 | 2017 2013; Winbanks et al, 2013).”
Background
Cited by
Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin
Mehdipour, M., Skinner, C., Wong, N., Lieb, M., Liu, C., Etienne, J., Kato, C., Kiprov, D., Conboy, M. J., & Conboy, I. M. (2020) · Aging · doi:10.18632/aging.103418 · Cited by 115
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
The influence of GDF11 on brain fate and function
Schafer, M. J., & LeBrasseur, N. K. (2019) · GeroScience · doi:10.1007/s11357-019-00054-6 · Cited by 39
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
Frohlich, J., & Vinciguerra, M. (2020) · GeroScience · doi:10.1007/s11357-020-00279-w · Cited by 28
Walton, K. L., Chen, J. L., Arnold, Q., Kelly, E., La, M., Lu, L., Lovrecz, G., Hagg, A., Colgan, T. D., Qian, H., et al. (2019) · Endocrinology · doi:10.1210/en.2019-00257 · Cited by 23
“causes systemic wasting (10, 28) and suggest that ele-”
Background
Metadata
- Authors
- Hammers, D. W., Merscham‐Banda, M., Hsiao, J. Y., Engst, S., Hartman, J. J., & Sweeney, H. L.
- Venue
- EMBO Molecular Medicine
- Published
- 2017-03-07
- Volume
- 9
- Issue
- 4
- Pages
- 531-544
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2592234332
- Cited by
- 115
- References
- 13
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.